Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury
Journal of Korean Neurosurgical Society
;
: 73-76, 2015.
Article
Dans Anglais
| WPRIM
| ID: wpr-190410
ABSTRACT
OBJECTIVE:
Tumor necrosis factor alpha (TNF-alpha) have proven effects in pathogenesis of neuroinflammation after spinal cord injury (SCI). Current study is designed to evaluate the effects of an anti-TNF-alpha agent, adalimumab, on spinal cord clip compression injury in rats.METHODS:
Thirty two male adult Wistar rats were divided into four groups (sham, trauma, infliximab, and adalimumab groups) and SCI was introduced using an aneurysm clip. Animals in treatment groups received 5 mg/kg subcutaneous adalimumab and infliximab right after the trauma. Malondialdehyde (MDA) levels were studied in traumatized spinal cord tissues 72 hours after the injury as a marker of lipid peroxidation.RESULTS:
Animals that received anti-TNF-alpha agents are found to have significantly decreased MDA levels. MDA levels were significantly different between the trauma and infliximab groups (p<0.01) and trauma and adalimumab groups (p=0.022). There was no significant difference in neurological evaluation of the rats using Tarlov scale.CONCLUSION:
These results suggest that, like infliximab, adalimumab has favorable effects on lipid peroxidation induced by spinal cord trauma in rats.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Moelle spinale
/
Traumatismes de la moelle épinière
/
Peroxydation lipidique
/
Facteur de nécrose tumorale alpha
/
Rat Wistar
/
Adalimumab
/
Infliximab
/
Anévrysme
/
Malonaldéhyde
Limites du sujet:
Animaux
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Journal of Korean Neurosurgical Society
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS